Table 2:

Treatment data

	Aged less than 70 years (n = 65)		Aged 70 or greater (n = 37)		P value
Number of chemotherapy cycles
Median (range)	6 (3–7)		6 (3–8)		NS
Mean (standard deviation)	5.7 (1.0)		5.8(1.1)
Relative dose intensity (mg/m2/week)
Doxorubicin*	15.6		13.5		0.001
Cyclophosphamide	236		220		0.04
Vincristine	0.6		0.5		0.02
Prednisone	158		150		NS
Rituximab	120		116		NS
	No.	%	No	%
Dose delay of 7 days or greater	12	23	11	30	NS
Chemotherapy Dose Reduction
At least one chemotherapy dose	12	18	27	73	0.001
Planned dose reduction at onset	3	5	8	22	0.008
Doxorubicin dose intensity*
At least 10mg/m2/week	63	98	33	89	0.04
Less than 10mg/m2/week	1	2	4	11
Average relative dose intensity^
Received 70% or greater of standard RDI	60	94	32	86	NS
Received less than 70% of standard RDI	4	6	5	14
G-CSF Use
Used as prophylaxis (any cycle)	43	66	37	100	0.001
Prophylaxis from cycle 1	18	28	34	92	0.001

^*One patient aged less than 70 received doxil in place of doxorubicin and is not included in the analysis

^{^}Relative dose intensity calculated using reference standard CHOP-R schedule – Doxorubicin 50mg/m² (day 1), Cyclophosphamide 750mg/m² (day 1), Vincristine 1.4mg/m²; max 2mg (day 1), Prednisone 100mg (day 1–5), and Rituximab 375mg/m² (day 1); GCSF: granulocyte colony stimulating factor